TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17577005
Drug: Adjusted-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose warfarin (6 trials, 2900 participants)
Study: 10507957
Drug: Aspirin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (6 trials, 3119 participants)
Study: 10507957
Drug: Adjusted-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose warfarin (5 trials, 2837 participants)
Study: 30961342
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate treatment group
Study: 30508196
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg once daily
Study: 22264885
Drug: 0.1% fluorometholone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% fluorometholone 3 times a day (steroid group)
Study: 22264885
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of steroid eye drops (no steroid group)
Study: 19429734
Drug: Self-reported adherence-satisfaction
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported adherence-satisfaction with taking medication
Study: 18257436
Drug: Adjuvant ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant ultrasound therapy
Study: 18257436
Drug: NSAIDs, exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs, exercise therapy, manipulative therapy, corticosteroid injection, acupuncture
Study: 1451219
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of glucose-free lidocaine 2%
Study: 1451219
Drug: 2.5 ml
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 ml of glucose-free lidocaine 2%
Study: 1451219
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml of glucose-free lidocaine 2%
Study: 3881598
Drug: 21-day treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 21-day treatment
Study: 31805855
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural analgesia with 6 ml/h of 0.25% bupivacaine during surgery and 6 ml/h of 0.125% bupivacaine for 24 h post-surgery.
Study: 28089476
Drug: ADMA levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADMA levels (0.9±0.2μmol/L)
Study: 28089476
Drug: Highest ADMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest ADMA quintile (≥1.07μmol/L)
Study: 28089476
Drug: SDMA levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDMA levels (4.3±1.4μmol/L)
Study: 26149722
Drug: Daily SMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SMS messages (direct, PIN-protected, coded) and transportation reimbursements (about $6 USD) for participants returning within seven days.
Study: 24047438
Drug: Single-dose azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose azithromycin (AZT) 1000 mg orally
Study: 24047438
Drug: Azithromycin (AZT)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (AZT) 500 mg daily for 9 and 14 days
Study: 24047438
Drug: Doxycycline (DOX)
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline (DOX) 200 mg for 21 days
Study: 20819978
Drug: Psilocybin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (0.2 mg/kg)
Study: 17944893
Drug: Normal hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal hospital diet plus 400‐mL oral nutritional supplements daily for 6 weeks
Study: 15547534
Drug: Foley catheter
Normalized name: Bard Foley Catheter 18FR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley catheter balloon inflated with 80 mL of sterile saline
Study: 15547534
Drug: Foley catheter
Normalized name: Bard Foley Catheter 18FR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley catheter balloon inflated with 30 mL of sterile saline
Study: 3305744
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality approach in rectal carcinoma patients (stages B2 and C)
Study: 22043463
Drug: Flapless implant
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flapless implant placement
Study: 29234747
Drug: Flap implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flap implant placement
Study: 19673983
Drug: Biophage-PA (therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biophage-PA (therapeutic bacteriophage preparation)
Study: 16495395
Drug: Itopride 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride 50 mg three times daily
Study: 17965059
Drug: Itopride 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride 100 mg three times daily
Study: 16495395
Drug: Itopride 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride 200 mg three times daily
Study: 16495395
Drug: Itopride (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride (combined doses)
Study: 16495395
Drug: Itopride (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride (100 mg and 200 mg)
Study: 14616590
Drug: AM149 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM149 1% (new formulation of propofol)
Study: 14616590
Drug: Disoprivan 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disoprivan 1% (standard formulation of propofol)
Study: 1637794
Drug: Fat/cholesterol supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat/cholesterol supplement (31 g fat, 650 mg cholesterol)
Study: 1637794
Drug: Fat/cholesterol supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat/cholesterol supplement
Study: 1637794
Drug: Fat-free supplement
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat-free supplement
Study: 3881654
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (azathioprine, prednisone, antithymocyte immunoglobulin)
Study: 31058977
Drug: HSV529 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSV529 vaccine
Study: 24373998
Drug: PT302 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT302 (4 mg)
Study: 24373998
Drug: PT302 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT302 (0.5 mg, 1 mg, 2 mg, 4 mg)
Study: 18839781
Drug: Highly active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly active antiretroviral therapy (HAART; zidovudine [ZDV], lamivudine, and nevirapine [NVP])
Study: 18839781
Drug: Short-course ZDV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course ZDV plus single-dose NVP (ZDV/NVP)
Study: 11986476
Drug: Short-course antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course antibiotic therapy (</=3 days)
Study: 11986476
Drug: Short-course antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course antibiotic therapy (single-dose or 1-day)
Study: 11986476
Drug: Short-course antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course antibiotic therapy (3-day)
Study: 10524723
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group received additional information about stop signals (three oral, one written) before injections.
Study: 7761218
Drug: Chemotherapy at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy at home
Study: 7761218
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in the hospital
Study: 2148014
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 20 mg TID
Study: 2148014
Drug: Domperidone (DP)
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (DP) 20 mg TID
Study: 2148014
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MPA and DP
Study: 6985836
Drug: Levamisole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (150 mg daily x 3)
Study: 25491704
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy only
Study: 25491704
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy combined with motivational interviewing and a peer support group
Study: 9737478
Drug: Enoxaparin, ticlopidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin, ticlopidine, and aspirin
Study: 9737478
Drug: Warfarin anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin anticoagulant treatment
Study: 22794665
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active treatment (Control)
Study: 21718265
Drug: Twice-weekly balance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly balance and tone exercises (control)
Study: 26363985
Drug: Locoregional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional treatment
Study: 26363985
Drug: No locoregional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No locoregional treatment
Study: 21156001
Drug: Low-calcium diet
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calcium diet + probiotic (2 g/kg diet)
Study: 21156001
Drug: Low-calcium diet
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calcium diet + prebiotic (2 g/kg diet)
Study: 21156001
Drug: Low-calcium diet
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calcium diet + synbiotic (mix of probiotic and prebiotic, each 2 g/kg diet)
Study: 21156001
Drug: Low-calcium diet
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calcium diet + organic acid (1.5 g/kg diet)
Study: 19922882
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg/d)
Study: 19922882
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg/d)
Study: 17097814
Drug: exercise+nicotine patch
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: exercise+nicotine patch
Study: 17097814
Drug: exercise+no nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: exercise+no nicotine patch
Study: 17097814
Drug: cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: cognitive behavior therapy (CBT)+nicotine patch
Study: 17097814
Drug: CBT+no nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBT+no nicotine patch
Study: 8363392
Drug: Enoxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin (200 mg/12 h for 3 days)
Study: 8363392
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (125 mg/12 h for 7 days)
Study: 3534857
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg every 8 hours for 1 month
Study: 3534857
Drug: Digoxin 0.25
Normalized name: digoxin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.25 mg once a day for 1 month
Study: 31291923
Drug: Mentalization-Based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-Based Treatment (MBT)
Study: 26888146
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human (rh)IGF‐I/rhIGF binding protein‐3 (IGFBP‐3) complex (30 mg/day)
Study: 26888146
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human (rh)IGF‐I/rhIGF binding protein‐3 (IGFBP‐3) complex (60 mg/day)
Study: 26888146
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human (rh)IGF‐I/rhIGF binding protein‐3 (IGFBP‐3) complex (30 mg/day or 60 mg/day)
Study: 24081940
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein powder and placebo pill
Study: 24081940
Drug: Venlafaxine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine and placebo pill
Study: 21725874
Drug: 2% KZC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% KZC and 2% TET cream (KCZ + TET group)
Study: 21725874
Drug: 2% KZC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% KZC cream (KCZ group)
Study: 21725874
Drug: 2% TET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% TET cream (TET group)
Study: 19370276
Drug: Midazolam 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.075 mg/kg and Dexamethasone 10 mg (MD group)
Study: 19370276
Drug: Midazolam 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.075 mg/kg (M group)
Study: 19370276
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg (D group)
Study: 19370276
Drug: Intravenous normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline (S group)
Study: 3665957
Drug: High-dose anticoagulants
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose anticoagulants
Study: 3665957
Drug: Oral warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral warfarin
Study: 3665957
Drug: Post-warfarin discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-warfarin discontinuation
Study: 20969563
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment and cream
Study: 16950289
Drug: Asthma medication
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asthma medication in adults
Study: 3898836
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with melphalan and prednisone
Study: 8845572
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with melphalan
Study: 8845572
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment with interferon alpha
Study: 8845572
Drug: Second-line treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line treatment for MM patients who are primary refractory to melphalan
Study: 8845572
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with melphalan and prednisone
Study: 2079452
Drug: cefadroxil 1
Normalized name: CEFADROXIL 1GM TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefadroxil 1 g tid (13 subjects)
Study: 2079452
Drug: co‐trimoxazole 160/800
Approvals — FDA: no, EMA: no, PMDA: no
Description: co‐trimoxazole 160/800 mg bd (23 subjects)
Study: 2079452
Drug: norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: norfloxacin 400 mg bd (35 subjects)
Study: 2079452
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (all agents)
Study: 31500670
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1.8 g/day for 16 weeks
Study: 28195952
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (n = 58)
Study: 28195952
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy and Usual care combined
Study: 16817913
Drug: peginterferon alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alpha‐2b and lamivudine combination
Study: 20943454
Drug: lamivudine monotherapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lamivudine monotherapy
Study: 8217354
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (CMF: cyclophosphamide, methotrexate, and 5-fluorouracil)
Study: 8217354
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant therapy (control)
Study: 8217354
Drug: Endocrine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine treatment after relapse
Study: 9865735
Drug: Chemotherapy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy after relapse
Study: 8217354
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (CMF) and No adjuvant therapy (control)
Study: 30160521
Drug: Top quintile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Top quintile (>185 mg/dl)
Study: 24941843
Drug: Dangfei Liganning
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dangfei Liganning Tablet (DLT), two tablets each time, three times per day for 4 weeks
Study: 24941843
Drug: Liver‐protecting Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver‐protecting Tablet (LT), four tablets each time, three times per day for 4 weeks
Study: 22502713
Drug: Psychosocial factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial factors (e.g., agreeableness, extraversion, stress, social support, self-efficacy)
Study: 18482155
Drug: Naltrexone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone monotherapy (50 mg naltrexone + sertraline placebo)
Study: 18482155
Drug: Naltrexone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone + sertraline (100 mg) plus nine sessions of medical management and supportive advice
Study: 12886816
Drug: Multimicronutrient supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimicronutrient supplementation (vitamin A, 1000 micrograms; vitamin B1, 1.4 mg; vitamin B2, 1.6 mg; vitamin B6, 1.7 mg; vitamin B12, 2.0 micrograms; folate, 150 micrograms; niacin, 16 mg; vitamin C, 50 mg; vitamin D, 5 micrograms; vitamin E, 8 mg; iron, 18 mg; zinc, 20 mg; copper, 2.0 mg; iodine, 150 micrograms; selenium, 40 micrograms)
Study: 8890674
Drug: Adjunctive medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive medication (lithium, perphenazine, or paroxetine)
Study: 8890674
Drug: No adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjunctive medication
Study: 4084667
Drug: Prednisolone hemisuccinate
Normalized name: prednisolone hemisuccinate
DrugBank: Prednisolone hemisuccinate (DB14633)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone hemisuccinate 1200 mg
Study: 4084667
Drug: Prednisolone hemisuccinate
Normalized name: prednisolone hemisuccinate
DrugBank: Prednisolone hemisuccinate (DB14633)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone hemisuccinate 75 mg
Study: 4084667
Drug: Prednisolone hemisuccinate
Normalized name: prednisolone hemisuccinate
DrugBank: Prednisolone hemisuccinate (DB14633)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone hemisuccinate (both doses)
Study: 30085292
Drug: Intranasal Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal Oxytocin (40 IU)
Study: 29661241
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation Therapy (CRT-O)
Study: 27712772
Drug: Average sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average sodium intake categories (<2,300, 2,300 to <3,600, 3,600 to <4,800, and ≥4,800 mg/24 h)
Study: 24999963
Drug: Elevated SDMA
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated SDMA (4th quartile, >1.38 μmol/L)
Study: 23356027
Drug: 1 year
Normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 year of WHO‐MDT plus an initial 1 month of daily ofloxacin
Study: 23356027
Drug: 1 month
Normalized name: LUPRON-PED 15MG (1 MONTH) SA INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 month of daily rifampicin and daily ofloxacin
Study: 18564278
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment alone (Control)
Study: 16403993
Drug: Lamotrigine (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (50-100 mg daily)
Study: 10937983
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose lisinopril (2.5-5.0 mg/day)
Study: 10937983
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose lisinopril (32.5-35.0 mg/day)
Study: 8901854
Drug: Beta-carotene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (20 mg)
Study: 8901854
Drug: Beta-carotene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (20 mg) in participants smoking at least 20 cigarettes daily
Study: 8901854
Drug: Beta-carotene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (20 mg) in participants smoking 5-19 cigarettes daily
Study: 8901854
Drug: Beta-carotene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (20 mg) in participants with higher alcohol intake (> or = 11 g of ethanol/day)
Study: 8901854
Drug: Beta-carotene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (20 mg) in participants with lower alcohol intake
Study: 6753891
Drug: Captopril (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25-50 mg three times daily)
Study: 6753891
Drug: Captopril +
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril + Hydrochlorothiazide (25-50 mg once daily)
Study: 6753891
Drug: Atenolol +
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol + Hydrochlorothiazide (25-50 mg once daily)